Bisphosphonates in Dentistry – State of the Art

1. Kuźnik A, Październiok-Holewa A, Jewula P, Kuźnik N. Bisphosphonates-much more than only drugs for bone diseases. Eur J Pharmacol. 2020;866:17277310.1016/j.ejphar.2019.172773Search in Google Scholar

2. Giger EV, Castagner B, Leroux JC. Biomedical applications of bisphosphonates. J Control Release 2013;167:175–188.10.1016/j.jconrel.2013.01.03223395668Search in Google Scholar

3. Jung J, Park JS, Righesso L, et al. Effects of an oral bisphosphonate and three intravenous bisphosphonates on several cell types in vitro. Clin Oral Investig. 2018;22:2527-2534.10.1007/s00784-018-2349-6Search in Google Scholar

4. Kos M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci. 2015;11:319-324.10.5114/aoms.2015.50964Search in Google Scholar

5. Di Fede O, Panzarella V, Mauceri R, et al. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. Biomed Res Int. 2018;2018:2684924. Published 2018 Sep 16.10.1155/2018/2684924Search in Google Scholar

6. Kates SL, Ackert-Bicknell CL. How do bisphosphonates affect fracture healing?. Injury. 2016;47 Suppl 1:S65-S68.10.1016/S0020-1383(16)30015-8Search in Google Scholar

7. Giger EV, Castagner B, Leroux JC. Biomedical applications of bisphosphonates. J Control Release 2013; 167: 175–188.10.1016/j.jconrel.2013.01.032Search in Google Scholar

8. Savino S, Toscano A, Purgatorio R, et al. Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis. Eur J Med Chem. 2018;158:184-200.10.1016/j.ejmech.2018.08.04430216851Search in Google Scholar

9. De Colli M, Tortorella P, Agamennone M, et al. Bisphosfonate matrix metalloproteinase inhibitors for the treatment of periodontitis: An in vitro study. Int J Mol Med. 2018;42:651-657.10.3892/ijmm.2018.364129717767Search in Google Scholar

10. Akram Z, Abduljabbar T, Kellesarian SV, Abu Hassan MI, Javed F, Vohra F. Efficacy of bisphosphonate as an adjunct to nonsurgical periodontal therapy in the management of periodontal disease: a systematic review. Br J Clin Pharmacol. 2017;83:444-454.10.1111/bcp.13147530648027718252Search in Google Scholar

11. Wayama MT, Yoshimura H, Ohba S, et al. Diminished Progression of Periapical Lesions with Zoledronic Acid in Ovariectomized Rats. J Endod. 2015;41:2002-2007.10.1016/j.joen.2015.08.029Search in Google Scholar

12. Silva RAB, Sousa-Pereira AP, Lucisano MP, et al. Alendronate inhibits osteocyte apoptosis and inflammation via IL-6, inhibiting bone resorption in periapical lesions of ovariectomized rats. Int Endod J. 2020;53:84-96.10.1111/iej.13206Search in Google Scholar

13. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393:364-376.10.1016/S0140-6736(18)32112-3Search in Google Scholar

14. Weitzmann MN. Bone and the Immune System. Toxicol Pathol. 2017;45:911-924.10.1177/0192623317735316574925429046115Search in Google Scholar

15. Tobeiha M, Moghadasian MH, Amin N, Jafarnejad S. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. Biomed Res Int. 2020;2020:6910312. Published 2020 Feb 19.10.1155/2020/6910312705348132149122Search in Google Scholar

16. Kenkre JS, Bassett J. The bone remodelling cycle. Ann Clin Biochem. 2018;55(3):308-327.10.1177/000456321875937129368538Search in Google Scholar

17. Holstein SA. A patent review of bisphosphonates in treating bone disease. Expert Opin Ther Pat. 2019;29:315-325.10.1080/13543776.2019.160818031023104Search in Google Scholar

18. Yu Z, Surface LE, Park CY, et al. Identification of a transporter complex responsible for the cytosolic entry of nitrogen-containing bisphosphonates. Elife. 2018;7:e36620. Published 2018 May 10.10.7554/eLife.36620602117229745899Search in Google Scholar

19. Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019;85:1052-1062.10.1111/bcp.13867653342630650219Search in Google Scholar

20. Dayanand P, Sandhyavenu H, Dayanand S, Martinez J, Rangaswami J. Role of Bisphosphonates in Vascular calcification and Bone Metabolism: A Clinical Summary. Curr Cardiol Rev. 2018;14:192-199.10.2174/1573403X14666180619103258613140929921207Search in Google Scholar

21. Zameer S, Najmi AK, Vohora D, Akhtar M. Bisphosphonates: Future perspective for neurological disorders. Pharmacol Rep. 2018;70:900-907.10.1016/j.pharep.2018.03.01130096489Search in Google Scholar

22. Noronha Oliveira M, Schunemann WVH, Mathew MT, et al. Can degradation products released from dental implants affect peri-implant tissues?. J Periodontal Res. 2018;53:1-11.10.1111/jre.1247928766712Search in Google Scholar

23. Pellegrini G, Francetti L, Barbaro B, Del Fabbro M. Novel surfaces and osseointegration in implant dentistry. J Investig Clin Dent. 2018;9:e12349.10.1111/jicd.1234929971928Search in Google Scholar

24. Turri A, Rossetti PH, Canullo L, et al. Prevalence of peri-implantitis in medically compromised patients and smokers: a systematic review. Int J Oral Maxillofac Implants. 2016;31:111-118.10.11607/jomi.414926800167Search in Google Scholar

25. Meyle J, Casado P, Fourmousis I, Kumar P, Quirynen M, Salvi GE. General genetic and acquired risk factors, and prevalence of peri-implant diseases - Consensus report of working group 1. Int Dent J. 2019;69 Suppl 2:3-6.10.1111/idj.1248931478573Search in Google Scholar

26. French D, Grandin HM, Ofec R. Retrospective cohort study of 4,591 dental implants: Analysis of risk indicators for bone loss and prevalence of peri-implant mucositis and peri-implantitis. J Periodontol. 2019;90:691-700.10.1002/JPER.18-0236684972930644101Search in Google Scholar

27. Ata-Ali J, Ata-Ali F, Peñarrocha-Oltra D, Galindo- Moreno P. What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res. 2016;27:e38-e4610.1111/clr.1252625406770Search in Google Scholar

28. de-Freitas NR, Lima LB, de-Moura MB, Veloso- Guedes CC, Simamoto-Júnior PC, de-Magalhães D. Bisphosphonate treatment and dental implants: A systematic review. Med Oral Patol Oral Cir Bucal. 2016;21:e644-e651. Published 2016 Sep 1.10.4317/medoral.20920500510527475681Search in Google Scholar

29. Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schiødt M, Klinge B. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis. Clin Oral Implants Res. 2018;29 Suppl 18:54-92.10.1111/clr.1328230306695Search in Google Scholar

30. Khoury F, Hidajat H. Extensive Autogenous Bone Augmentation and Implantation in Patients Under Bisphosphonate Treatment: A 15-Case Series. Int J Periodontics Restorative Dent. 2016;36:9-1810.11607/prd.260826697549Search in Google Scholar

31. Kellesarian SV, Subhi ALHarthi S, Saleh Binshabaib M, Javed F. Effect of local zoledronate delivery on osseointegration: a systematic review of preclinical studies. Acta Odontol Scand. 2017;75:530-541.10.1080/00016357.2017.135099428708011Search in Google Scholar

32. He Y, Bao W, Wu XD, Huang W, Chen H, Li Z. Effects of Systemic or Local Administration of Zoledronate on Implant Osseointegration: A Preclinical Meta-Analysis. Biomed Res Int. 2019;2019:9541485. Published 2019 Sep 22.10.1155/2019/9541485677894131663000Search in Google Scholar

33. Liapatas S, Nakou M, Rontogianni D. Inflammatory infiltrate of chronic periradicular lesions: an immunohistochemical study. Int Endod J. 2003.10.1046/j.1365-2591.2003.00627.x12823701Search in Google Scholar

34. França TRT, Ramos-Perez FMM, Pontual ADA, Castro JFL, Bonan PRF, Perez DEDC. Effects of Zoledronic Acid in Experimental Periapical Lesions in Rats: An Imaging and Histological Analysis. Braz Dent J. 2017;28:566-572.10.1590/0103-644020160155829215680Search in Google Scholar

35. Wayama MT, Yoshimura H, Ohba S, et al. Diminished Progression of Periapical Lesions with Zoledronic Acid in Ovariectomized Rats. J Endod. 2015;41:2002-2007.10.1016/j.joen.2015.08.02926490005Search in Google Scholar

36. Lertpimonchai A, Rattanasiri S, Arj-Ong Vallibhakara S, Attia J, Thakkinstian A. The association between oral hygiene and periodontitis: a systematic review and meta-analysis. Int Dent J. 2017;67:332-343.10.1111/idj.12317572470928646499Search in Google Scholar

37. Martinho FC, Leite FR, Nóbrega LM, et al. Comparison of Fusobacterium nucleatum and Porphyromonas gingivalis Lipopolysaccharides Clinically Isolated from Root Canal Infection in the Induction of Pro-Inflammatory Cytokines Secretion. Braz Dent J. 2016;27:202-207.10.1590/0103-644020160057227058385Search in Google Scholar

38. Frencken JE, Sharma P, Stenhouse L, Green D, Laverty D, Dietrich T. Global epidemiology of dental caries and severe periodontitis - a comprehensive review. J Clin Periodontol. 2017;44 Suppl 18:S94-S105.10.1111/jcpe.1267728266116Search in Google Scholar

39. De Colli M, Tortorella P, Agamennone M, et al. Bisphosfonate matrix metalloproteinase inhibitors for the treatment of periodontitis: An in vitro study. Int J Mol Med. 2018;42:651-657.10.3892/ijmm.2018.364129717767Search in Google Scholar

40. Buduneli E, Vardar-Şengül S, Buduneli N, Atilla G, Wahlgren J, Sorsa T. Matrix Metalloproteinases, Tissue Inhibitor of Matrix Metalloproteinase-1, and Laminin- 5 γ2 Chain Immunolocalization in Gingival Tissue of Endotoxin-Induced Periodontitis in Rats: Effects of Low-Dose Doxycycline and Alendronate. J Periodontol. 2007;78:127-134.10.1902/jop.2007.05045129539192Search in Google Scholar

41. Soundia A, Hadaya D, Esfandi N, et al. Zoledronate Impairs Socket Healing after Extraction of Teeth with Experimental Periodontitis. J Dent Res. 2018;97:312-320.10.1177/0022034517732770583318228954199Search in Google Scholar

42. Kanoriya D, Pradeep AR, Singhal S, Garg V, Guruprasad CN. Synergistic Approach Using Platelet-Rich Fibrin and 1% Alendronate for Intrabony Defect Treatment in Chronic Periodontitis: A Randomized Clinical Trial. J Periodontol. 2016;87:1427-1435.10.1902/jop.2016.15069827562221Search in Google Scholar

43. Kanoriya D, Pradeep AR, Garg V, Singhal S. Mandibular Degree II Furcation Defects Treatment With Platelet- Rich Fibrin and 1% Alendronate Gel Combination: A Randomized Controlled Clinical Trial. J Periodontol. 2017;88:250-258.10.1902/jop.2016.16026927712462Search in Google Scholar

44. Camacho-Alonso F, Davia-Peña RS, Vilaplana-Vivo C, Tudela-Mulero MR, Merino JJ, Martínez-Beneyto Y. Synergistic effect of photodynamic therapy and alendronate on alveolar bone loss in rats with ligature-induced periodontitis. J Periodontal Res. 2018;53:306-314.10.1111/jre.1251529086417Search in Google Scholar

45. Sharma A, Raman A, Pradeep AR. Role of 1% alendronate gel as adjunct to mechanical therapy in the treatment of chronic periodontitis among smokers. J Appl Oral Sci. 2017;25:243-249.10.1590/1678-7757-2016-0201548224628678942Search in Google Scholar

46. Hiltunen AK, Skogman ME, Rosenqvist K, et al. Bioactive glass combined with bisphosphonates provides protection against biofilms formed by the periodontal pathogen Aggregatibacter actinomycetemcomitans. Int J Pharm. 2016;501:211-220.10.1016/j.ijpharm.2016.02.00626854428Search in Google Scholar

47. Kuroshima S, Sasaki M, Sawase T. Medication-related osteonecrosis of the jaw: A literature review. J oral Biosci. 2019;61:99–104. * Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication- related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2017;10:CD012432. Published 2017 Oct 6.10.1016/j.job.2019.03.005Search in Google Scholar

48. Khan A, Morrison A, Cheung A, Hashem W, Compston J. Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015. Osteoporos Int. 2016;27:853-859.10.1007/s00198-015-3335-326493811Search in Google Scholar

49. Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177-187.10.1016/j.ctrv.2018.06.00730055439Search in Google Scholar

50. Holtmann H, Lommen J, Kübler NR, et al. Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials. J Int Med Res. 2018;46:4277-4296.10.1177/0300060518788987616633230091399Search in Google Scholar

51. Nicolatou-Galitis O, Kouri M, Papadopoulou E, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019;27:383-394.10.1007/s00520-018-4501-x30353228Search in Google Scholar

52. Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D. Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo. 2017;69:9-15.10.4081/reumatismo.2017.98328535616Search in Google Scholar

53. Mânea HC, Urechescu HC, Balica NC, et al. Bisphosphonates- induced osteonecrosis of the jaw - epidemiological, clinical and histopathological aspects. Rom J Morphol Embryol. 2018;59:825-831.Search in Google Scholar

54. Ruggiero SL. Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw. Oral Maxillofac Surg Clin North Am. 2015;27:479-487.10.1016/j.coms.2015.06.00826293329Search in Google Scholar

55. Ruggiero S, Dodson T, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 2014;72:1938–56.10.1016/j.joms.2014.04.03125234529Search in Google Scholar

56. Dodson TB. Risk Factors.Oral Maxillofac Surg Clin North Am. 2015; 27: 509-516.10.1016/j.coms.2015.06.00326362367Search in Google Scholar

57. Di Fede O, Panzarella V, Mauceri R, et al. The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention. Biomed Res Int. 2018;2018:2684924. Published 2018 Sep 16.10.1155/2018/2684924616420030306086Search in Google Scholar

58. Mücke T, Krestan CR, Mitchell DA, Kirschke JS, Wutzl A. Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review. Semin Musculoskelet Radiol. 2016;20:305-314.10.1055/s-0036-159236727741546Search in Google Scholar

59. Kos M, Junka A, Smutnicka D, Bartoszewicz M, Kurzynowski T, Gluza K. Pamidronate enhances bacterial adhesion to bone hydroxyapatite. Another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg. 2013;71:1010–6.10.1016/j.joms.2012.12.005Search in Google Scholar

60. Kos M. Incidence and risk predictors for osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Arch Med Sci. 2015;11:319-324.10.5114/aoms.2015.50964442424925995747Search in Google Scholar